- Exploring efficiencies from eTMF with Cancer Research UK
- GSK’s Zejula meets primary goal in Phase III ovarian cancer trial
- Trials data suggests Cosentyx from Novartis will change psoriasis market
- Eligibility criteria for clinical trials report challenges in representing LN patients
- Celltrion implements Veeva Vault eTMF to improve visibility into clinical trial activities
Abeona to initiate Phase III trial of EB-101 to treat RDEB
Abeona Therapeutics is ready to initiate its pivotal Phase III clinical trial, VIITAL, to evaluate EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
Bristol-Myers and bluebird report positive data from myeloma study
Bristol-Myers Squibb and bluebird bio have reported positive data from the ongoing Phase I study (CRB-402) of bb21217 for relapsed/refractory multiple myeloma (R/RMM) in patients who did not respond to prior treatments.
Sangamo’s gene therapy shows promise in beta thalassemia study
Preliminary results from Sangamo Therapeutics’ Phase I/II THALES clinical trial of ST-400 have demonstrated a favourable profile of the gene therapy in treating transfusion-dependent beta thalassemia (TDT) patients.
3DforScience Showed its Visual Solutions at ESMO Congress Barcelona
The European Society for Medical Oncology (ESMO) Congress took place Barcelona from 27 September to 1 October 2019. This was an annual gathering of the leading European professional organisation for medical oncology, with more than 17,000 oncology professionals from over 130 countries.
Unlearn.AI enhances Alzheimer’s drug through machine learning
First machine-learning (ML) platform developer Unlearn.AI has reported that its machine learning (ML) platform is capable of providing digital patient records designed to supplement actual control patients in clinical trials of Alzheimer’s disease.
Kite reports positive results of Yescarta in B-cell lymphoma
Gilead subsidiary Kite has announced positive long-term data from the ZUMA-1 study of Yescarta (axicabtagene ciloleucel) in adults suffering from refractory large B-cell lymphoma.
Biohaven to continue testing troriluzole in Alzheimer’s patients
Biohaven Pharmaceutical has received notification from the independent Data Safety Monitoring Board (DSMB) to continue its Phase II/III T2 Protect AD study of troriluzole for the treatment of mild-to-moderate Alzheimer's disease.
Ipsen places hold on paediatric patients in palovarotene’s studies
Ipsen has placed a partial clinical hold on all global sites of the Phase II PVO-1A-202/204, PVO-2A-201, and Phase III PVO-1A-301 clinical trials assessing palovarotene.
November’s top news stories
Eli Lilly and Boehringer Ingelheim started a Phase III clinical trial, EMPULSE, to evaluate whether Jardiance (empagliflozin) improves acute heart failure, and The Janssen Pharmaceutical Companies of Johnson & Johnson is reimagining digital clinical trial design with the launch of a new study. Clinicaltrialsarena.com wraps up key headlines from November 2019.
Arecor’s ultra-rapid acting insulin shows promise in Phase I trial
UK-based biopharmaceutical firm Arecor has announced that its ultra-rapid acting insulin candidate, AT247, demonstrated encouraging pharmacokinetic and pharmacodynamic profiles in a Phase I clinical trial.